Stock Events

Stock Events

IRulya Therapeutics 

$27.87
64
-$4.53-13.98%Tuesday 19:59

Statistics

Day High
37
Day Low
29.84
52W High
910
52W Low
15.1
Volume
138,744
Avg. Volume
30,979
Mkt Cap
28.35M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 18Expected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-28.02
6.52
41.06
75.6
Expected EPS
-1.385
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-83.98MNet Income

Analyst Ratings

$62.50Average Price Target
The highest estimate is ⁦82.00⁩.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
83%
Hold
17%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow QNCX. It's not an investment recommendation.
Microsoft
9
MSFT
Apple
8
AAPL
Amazon
8
AMZN
Tesla
8
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.36B
CRISPR Therapeutics AG focuses on the development of gene-based medicines, including therapies for genetic diseases, competing in the same innovative healthcare space as Quince.
Editas Medicine
EDIT
Mkt Cap402.38M
Editas Medicine, Inc. works on editing genes to treat genetic diseases, directly competing with Quince's approach to addressing genetic disorders.
Intellia Therapeutics
NTLA
Mkt Cap1.72B
Intellia Therapeutics, Inc. is a leading developer of CRISPR/Cas9 gene-editing therapies for genetic diseases, making it a direct competitor in the genetic medicine field.
Voyager Therapeutics
VYGR
Mkt Cap150.96M
Voyager Therapeutics, Inc. specializes in the development of gene therapies for neurodegenerative diseases, competing in the broader market of genetic disorder treatments.
Protagonist Therapeutics
PTGX
Mkt Cap9.06B
Protagonist Therapeutics, Inc. is engaged in the discovery and development of novel peptide-based drugs, which could compete with Quince's therapeutic approaches in a broader sense.
Fate Therapeutics
FATE
Mkt Cap277.98M
Fate Therapeutics, Inc. is involved in the development of programmed cellular immunotherapies for cancer and immune disorders, competing in the innovative treatment space.
Regenxbio
RGNX
Mkt Cap490.48M
REGENXBIO Inc. focuses on the development, commercialization, and licensing of recombinant adeno-associated virus (AAV) gene therapy, which competes with Quince's focus on regenerative medicine and genetic therapies.

About

Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
Show More
CEO
Dirk Thye
Employees
38
Country
United States
ISIN
US22053A3059

Listings

XNAS
US
IRLA
NASDAQ
US
QNCX
BOATS
BOATS
QNCX.BOATS

0 Comments

Share your thoughts

FAQs

What is IRulya Therapeutics stock price today?▼
The current price of QNCX is $27.87 USD — it has decreased by -13.98% in the past 24 hours. Watch IRulya Therapeutics stock price performance more closely on the chart.
What is IRulya Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange IRulya Therapeutics stocks are traded under the ticker QNCX.
Is IRulya Therapeutics stock price growing?▼
QNCX stock has fallen by -5.07% compared to the previous week, the month change is a -3.38% fall, over the last year IRulya Therapeutics has showed a -92.96% decrease.
What is IRulya Therapeutics market cap?▼
Today IRulya Therapeutics has the market capitalization of 28.35M
When is the next IRulya Therapeutics earnings date?▼
IRulya Therapeutics is going to release the next earnings report on November 18, 2026.
What were IRulya Therapeutics earnings last quarter?▼
QNCX earnings for the last quarter are -12.31 USD per share, whereas the estimation was -28.02 USD resulting in a +56.07% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is IRulya Therapeutics revenue for the last year?▼
IRulya Therapeutics revenue for the last year amounts to 0 USD.
What is IRulya Therapeutics net income for the last year?▼
QNCX net income for the last year is -83.98M USD.
How many employees does IRulya Therapeutics have?▼
As of October 15, 2026, the company has 38 employees.
In which sector is IRulya Therapeutics located?▼
IRulya Therapeutics operates in the Health & Wellness sector.
When did IRulya Therapeutics complete a stock split?▼
The last stock split for IRulya Therapeutics was on June 30, 2026 with a ratio of 1:20.
Where is IRulya Therapeutics headquartered?▼
IRulya Therapeutics is headquartered in SOUTH SAN FRANCISCO, United States.